Dengue virus antibodies in blood donors from an endemic area

Rodríguez, D. Rodríguez; Garza‐Rodríguez, María Lourdes; Chavarria, A. M.; Ramos‐Jiménez, Javier; Rivera, Moisés Hinojosa; Taméz, Rogelio Cazares; Farfán-Ale, José A.; Rivas-Estilla, Ana María

doi:10.1111/j.1365-3148.2009.00922.x

Cited by 23 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the true incidence of transfusion‐transmitted dengue is unknown because there is no surveillance for such events, and if a case is suspected, it is difficult to prove transfusion transmission (vs. vector‐borne transmission) in recipients from endemic countries. Nevertheless, transfusion risk models and assessments of viremia prevalence among blood donations indicate the potential for transfusion transmission of DENV in endemic areas 6‐8,11,12 . Risk is high in endemic areas as most DENV infections are asymptomatic and the viremia is high titered, long lasting, and detectable among asymptomatic individuals.…”

Section: Dengue Virus and Its Transmissionmentioning

confidence: 99%

Dengue: a potential transfusion‐transmitted disease

Tomashek¹,

Margolis²

2011

Transfusion

View full text Add to dashboard Cite

DENGUE VIRUS AND ITS TRANSMISSIOND engue is caused by four related RNA viruses of the genus Flavivirus, dengue virus (DENV)-1, -2, -3, and -4. Infection with DENV is usually asymptomatic but each DENV is capable of causing the full spectrum of clinical disease from mild, undifferentiated acute febrile illness, to classic dengue fever and more severe disease including dengue hemorrhagic fever and dengue shock syndrome. Severe disease manifestations including hypovolemic shock and clinically significant hemorrhage are more commonly observed among patients during their second or subsequent episodes of DENV infection. 1 Infection with one DENV produces lifelong immunity against that DENV type and short-term (Յ2 months) cross-protection against infection with the other three DENVs. Therefore, an individual has a lifetime risk of up to four DENV infections.DENVs are transmitted from person to person through the bite of an infected Aedes aegypti mosquito (less commonly Aedes albopictus or Aedes polynesiensis). 2 Unlike other related flaviviruses such as West Nile virus, humans are the main amplifying host for DENV. While there is a sylvatic nonhuman primate cycle of DENV transmission, it rarely crosses to humans, and antibodies to the sylvatic virus appear to protect against human DENV. The transmission cycle begins when a mosquito ingests DENV in a blood meal from an infected person (Fig. 1). DENV replicates and disseminates within the mosquito and reaches the salivary glands after 8 to 12 days (extrinsic incubation period). Higher ambient temperatures may reduce the extrinsic incubation period and increase the chance they will infect a human before dying. 3 The mosquito remains infectious for life (typically less than 1 month) and can transmit infection with 10 2 viral particles. 4 DENV replicates in humans for an intrinsic incubation period of 3 to 14 days before symptom onset. Infected persons can transmit DENV to mosquitoes as early as 1 to 2 days before symptoms develop 5 and throughout the approximately 7-day viremic period. Infected persons, even those who remain asymptomatic, have concentrations as high as 10 7 viral RNA copies per milliliter of blood. 6,7 During the viremic period, which occurs in symptomatic and asymptomatic infections, DENV can become a blood-borne infection. 8 Cases of dengue after receipt of blood products or donor organs or tissue and after occupational exposure in a health care setting have been reported. 8-10 However, the true incidence of transfusiontransmitted dengue is unknown because there is no surveillance for such events, and if a case is suspected, it is difficult to prove transfusion transmission (vs. vector-borne transmission) in recipients from endemic countries. Nevertheless, transfusion risk models and assessments of viremia prevalence among blood donations indicate the potential for transfusion transmission of DENV in endemic areas. [6][7][8]11,12 Risk is high in endemic areas as most DENV infections are asymptomatic and the viremia is high titered, long lasting, and detec...

show abstract

Section: Dengue Virus and Its Transmissionmentioning

confidence: 99%

Dengue: a potential transfusion‐transmitted disease

Tomashek¹,

Margolis²

2011

Transfusion

View full text Add to dashboard Cite

show abstract

“…DENV infection is nationally notifiable in Mexico (Rojo-Medina, 2014), but the presence of subclinical infections and the lack of recent seroprevalence studies in blood donors have prevented an accurate estimation of risk of infection by DENV through blood transfusion (Grange et al, 2014). We previously reported that 2% of blood donors from Nuevo Leon state, an endemic area for dengue in Mexico, showed anti-DENV antibodies in 2007 (Rodríguez Rodríguez et al, 2009). Our objective was to assess whether the seroprevalence of anti-DENV antibodies remains constant in blood donors over time and compare it with routine serologic markers.…”

mentioning

confidence: 99%

Constant risk of dengue virus infection by blood transfusion in an endemic area in Mexico

Arellanos-Soto

Cruz

Mendoza-Tavera

et al. 2015

Transfusion Medicine

Self Cite

View full text Add to dashboard Cite

Dear Sir,Dengue virus (DENV) infection is endemic in Mexico causing major public health problems (Gómez Dantés et al., 2014). It is transmitted largely through the vector mosquito Aedes aegypti (Brathwaite Dick et al., 2012). Increasing reports have showed dengue viremia in blood donors in endemic areas Mohammed et al., 2008) and transmission of DENV by blood transfusion has been recently documented in five cases (Stramer et al., 2012), therefore, DENV infection poses a risk for transfusion safety. DENV infection is nationally notifiable in Mexico (Rojo-Medina, 2014), but the presence of subclinical infections and the lack of recent seroprevalence studies in blood donors have prevented an accurate estimation of risk of infection by DENV through blood transfusion (Grange et al., 2014). We previously reported that 2% of blood donors from Nuevo Leon state, an endemic area for dengue in Mexico, showed anti-DENV antibodies in 2007 (Rodríguez Rodríguez et al., 2009). Our objective was to assess whether the seroprevalence of anti-DENV antibodies remains constant in blood donors over time and compare it with routine serologic markers.

show abstract

“…[15] Moreover, none had clinical features of acute brucellosis or dengue fever, while only 2% of the overall samples were reactive for anti-dengue virus IgM antibodies. It is very unlikely that our patient and his mother both had brucellosis and dengue fever simultaneously.…”

Section: Discussionmentioning

confidence: 99%

Coincidence of acute Brucella hepatitis and dengue fever or serologic cross-reactivity?

Bzeizi¹,

Benmousa²,

Sanai³

2010

Saudi J Gastroenterol

View full text Add to dashboard Cite

Hepatic involvement in brucellosis is not uncommon since 10-20% of patient infected with brucella species can have abnormal liver function tests. The usual presentation of brucella hepatitis is in the form of chronic granulomatous hepatitis with mild to moderate elevation of liver enzymes, while acute hepatitis is rare. We report a young patient who presented with acute brucella-induced hepatitis and co-infection with dengue hemorrhagic virus resulting in severe elevation of liver enzymes and absence of granuloma on histology. His mother also simultaneously tested positive for both infections. The patient responded well to anti-brucella therapy with normalization of his liver profile. We discuss, herein, the hepatic involvement of these two infections and discuss the possible serological cross-reactivity between brucella and dengue fever virus.

show abstract

Dengue virus antibodies in blood donors from an endemic area

Cited by 23 publications

References 25 publications

Dengue: a potential transfusion‐transmitted disease

Dengue: a potential transfusion‐transmitted disease

Constant risk of dengue virus infection by blood transfusion in an endemic area in Mexico

Coincidence of acute Brucella hepatitis and dengue fever or serologic cross-reactivity?

Contact Info

Product

Resources

About